This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination…
Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in…
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary…
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system…
High Impact Session presented at Heart Rhythm Society's Congress in ChicagoFirst time showing results of new Less Invasive approachImprovement in…
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements seen across all six DLQI Domains indicating broad,…
Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable TolerabilityMIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC,…
March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the Strength of Unprecedented Results from the Positive Phase…
March 14, 2026 10:15 ET | Source: Senseonics Holdings, Inc. New data shows positive real-world impact of the world’s first…